RxDoctor Payments Data

Philip Veatch, MD

Internal Medicine · Albemarle, NCNPI 1174503718

Payments from drug & device makers

$10,173in general payments, 2019–2025

Across 657 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$985
  • AstraZeneca$976
  • Lilly USA, LLC$762
  • AbbVie$734
  • Amgen$604
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$10,05399%
  • Education$1191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,173 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$257,576
Medicare patients
526
Services billed
5,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$146,240
JardianceEmpagliflozin81$96,018
OzempicSemaglutide42$64,131
MounjaroTirzepatide39$45,833
XareltoRivaroxaban51$45,167
FarxigaDapagliflozin Propanediol40$45,049
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog64$40,976
JanuviaSitagliptin Phosphate29$34,089
Tresiba Flextouch U-200Insulin Degludec28$32,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,320
MyrbetriqMirabegron22$24,018
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$16,436
Tresiba Flextouch U-100Insulin Degludec26$12,984
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$6,655
Combivent RespimatIpratropium/Albuterol Sulfate13$6,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$985$146,240160 claims
Boehringer IngelheimJardiance, Combivent Respimat$564$102,47994 claims
Novo NordiskOzempic$1,383$64,13142 claims
Lilly USA, LLCMounjaro$762$45,83339 claims
Johnson & JohnsonXarelto$153$45,16751 claims
AstraZenecaFarxiga$976$45,04940 claims
MerckJanuvia$130$34,08929 claims
GSKTrelegy Ellipta, Shingrix$349$32,66957 claims
Astellas Pharma US IncMyrbetriq$371$24,01822 claims
AbbVieSynthroid$734$3,51228 claims
Sanofi-aventis U.S. LLCLantus$203$2,79722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Albemarle

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →